ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,786Medicare Part D Prescriptions Filled, Including Refills

Rank: 432 out of 2343

$392K Total Retail Price of All Prescriptions

Rank: 928 out of 2343

318 Patients Receiving at Least One Drug in Part D
95%Patients 65 Years and Older
53% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Pennsylvania
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

3% of this provider’s 318 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

1% of this provider’s 10,477 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$36 was the average price of a prescription from this provider, compared to $58 among peers.

Prescriptions per Patient

34 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Pennsylvania
AMLODIPINE BESYLATE 745 727 1 5
HYDROCHLOROTHIAZIDE 723 686 2 11
SIMVASTATIN 605 584 3 1
LISINOPRIL 389 363 4 3
ALENDRONATE SODIUM 298 298 5 28
ATENOLOL 274 274 6 12
METFORMIN HCL ER 261 261 7 88
ATORVASTATIN CALCIUM 256 254 8 10
NIFEDIPINE ER 248 248 9 89
OMEPRAZOLE 240 236 10 4
METOPROLOL TARTRATE 234 219 11 7
FUROSEMIDE 231 230 12 6
LOVASTATIN 221 221 13 47
METOPROLOL SUCCINATE 215 203 14 14
LEVOTHYROXINE SODIUM 192 176 15 2
GLIPIZIDE XL 192 192 15 84
BYSTOLIC 172 172 17 123
DOXAZOSIN MESYLATE 169 169 18 98
LOSARTAN POTASSIUM 161 158 19 19
BENICAR 142 142 20 93
LISINOPRIL-HYDROCHLOROTHIAZIDE 142 142 20 42
TRAMADOL HCL 130 129 22 25
METFORMIN HCL 130 115 22 9
PRAVASTATIN SODIUM 119 119 24 15
KLOR-CON 8 117 117 25 226
GLIPIZIDE ER 109 102 26 115
RANITIDINE HCL 107 104 27 43
POTASSIUM CHLORIDE 96 90 28 18
WARFARIN SODIUM 91 91 29 8
CRESTOR 91 91 29 30
DIOVAN 90 90 31 23
FELODIPINE ER 86 86 32 116
PANTOPRAZOLE SODIUM 81 81 33 22
ALLOPURINOL 80 80 34 31
ENALAPRIL MALEATE 79 79 35 58
DONEPEZIL HCL 73 73 36 21
JANUVIA 72 72 37 50
HYDRALAZINE HCL 72 69 37 92
VENTOLIN HFA 61 60 39 79
COLCRYS 59 59 40 166
TAMSULOSIN HCL 59 52 40 29
LIPITOR 58 58 42 78
LOSARTAN-HYDROCHLOROTHIAZIDE 57 57 43 64
BENAZEPRIL HCL 56 56 44 113
NAPROXEN 54 54 45 108
LEVOCETIRIZINE DIHYDROCHLORIDE 53 53 46 223
GLYBURIDE 53 51 R 46 62
SPIRIVA 51 51 48 48
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.